CN110786516A - Nutritional supplement suitable for perimenopausal women - Google Patents
Nutritional supplement suitable for perimenopausal women Download PDFInfo
- Publication number
- CN110786516A CN110786516A CN201810867012.2A CN201810867012A CN110786516A CN 110786516 A CN110786516 A CN 110786516A CN 201810867012 A CN201810867012 A CN 201810867012A CN 110786516 A CN110786516 A CN 110786516A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- folic acid
- group
- essence
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015872 dietary supplement Nutrition 0.000 title description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 115
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 94
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 61
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 60
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 60
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 60
- 239000011710 vitamin D Substances 0.000 claims abstract description 60
- 229940046008 vitamin d Drugs 0.000 claims abstract description 60
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 55
- 239000011724 folic acid Substances 0.000 claims abstract description 55
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 55
- 229940046009 vitamin E Drugs 0.000 claims abstract description 55
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 55
- 239000011709 vitamin E Substances 0.000 claims abstract description 55
- 235000019152 folic acid Nutrition 0.000 claims abstract description 52
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 43
- 229960000304 folic acid Drugs 0.000 claims abstract description 43
- 229940088594 vitamin Drugs 0.000 claims abstract description 21
- 229930003231 vitamin Natural products 0.000 claims abstract description 21
- 235000013343 vitamin Nutrition 0.000 claims abstract description 21
- 239000011782 vitamin Substances 0.000 claims abstract description 21
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 16
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 15
- 235000013402 health food Nutrition 0.000 claims abstract description 13
- 235000016709 nutrition Nutrition 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims abstract description 5
- 230000035764 nutrition Effects 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 18
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 239000007901 soft capsule Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000007910 chewable tablet Substances 0.000 claims description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 4
- 239000007902 hard capsule Substances 0.000 claims description 4
- 229960000984 tocofersolan Drugs 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims description 3
- 206010067371 Menopausal depression Diseases 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 235000001465 calcium Nutrition 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 229940105150 5-methyltetrahydrofolic acid Drugs 0.000 claims description 2
- 235000002414 D-alpha-tocopherylacetate Nutrition 0.000 claims description 2
- 239000011740 D-alpha-tocopherylacetate Substances 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 claims description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 claims description 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 2
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 2
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims description 2
- 235000008207 calcium folinate Nutrition 0.000 claims description 2
- 239000011687 calcium folinate Substances 0.000 claims description 2
- 229940039770 d-alpha-tocopheryl acetate Drugs 0.000 claims description 2
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 claims description 2
- 229960002293 leucovorin calcium Drugs 0.000 claims description 2
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims description 2
- 229940065207 methylfolic acid Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000011653 vitamin D2 Substances 0.000 claims description 2
- 239000011647 vitamin D3 Substances 0.000 claims description 2
- 235000004835 α-tocopherol Nutrition 0.000 claims description 2
- 239000002076 α-tocopherol Substances 0.000 claims description 2
- 150000002224 folic acids Chemical class 0.000 claims 3
- 229960005069 calcium Drugs 0.000 claims 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 claims 1
- 230000002787 reinforcement Effects 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 abstract description 10
- 229930003270 Vitamin B Natural products 0.000 abstract description 9
- 235000019156 vitamin B Nutrition 0.000 abstract description 9
- -1 compound vitamin Chemical class 0.000 abstract description 8
- 239000000262 estrogen Substances 0.000 abstract description 5
- 229940011871 estrogen Drugs 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 210000000748 cardiovascular system Anatomy 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000000047 product Substances 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 27
- 239000000843 powder Substances 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 16
- 235000013399 edible fruits Nutrition 0.000 description 15
- 238000002156 mixing Methods 0.000 description 14
- 125000003929 folic acid group Chemical group 0.000 description 13
- 210000000689 upper leg Anatomy 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 9
- 229940014144 folate Drugs 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 230000037182 bone density Effects 0.000 description 7
- 229940118019 malondialdehyde Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229960004793 sucrose Drugs 0.000 description 7
- 238000013459 approach Methods 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000009245 menopause Effects 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 244000099147 Ananas comosus Species 0.000 description 3
- 235000007119 Ananas comosus Nutrition 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 3
- 244000131522 Citrus pyriformis Species 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000009806 oophorectomy Methods 0.000 description 3
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 239000008354 sodium chloride injection Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MRBKEAMVRSLQPH-UHFFFAOYSA-N 3-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1 MRBKEAMVRSLQPH-UHFFFAOYSA-N 0.000 description 2
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 2
- 244000298697 Actinidia deliciosa Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 235000004936 Bromus mango Nutrition 0.000 description 2
- 244000241235 Citrullus lanatus Species 0.000 description 2
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 description 2
- 240000000171 Crataegus monogyna Species 0.000 description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 2
- 244000241257 Cucumis melo Species 0.000 description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N Indigo Chemical compound N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000014826 Mangifera indica Nutrition 0.000 description 2
- 240000007228 Mangifera indica Species 0.000 description 2
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000009184 Spondias indica Nutrition 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 244000263375 Vanilla tahitensis Species 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 230000037118 bone strength Effects 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000007766 cera flava Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OAJLVMGLJZXSGX-NDSREFPTSA-L (2r,3s,4s,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12 Chemical compound [Co+3].O[C@H]1[C@H](O)[C@@H]([CH2-])O[C@H]1N1C2=NC=NC(N)=C2N=C1.C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O OAJLVMGLJZXSGX-NDSREFPTSA-L 0.000 description 1
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 241001409018 Anthracothorax viridis Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000006025 Durio zibethinus Nutrition 0.000 description 1
- 240000000716 Durio zibethinus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000000940 FEMA 2235 Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 235000007270 Gaultheria hispida Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 241000581835 Monodora junodii Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 235000009134 Myrica cerifera Nutrition 0.000 description 1
- 244000269152 Myrica pensylvanica Species 0.000 description 1
- 235000012851 Myrica pensylvanica Nutrition 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 244000288157 Passiflora edulis Species 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 241000287420 Pyrus x nivalis Species 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000482268 Zea mays subsp. mays Species 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 description 1
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
- 235000018889 capsanthin Nutrition 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 150000001867 cobalamins Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000010482 emotional regulation Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 239000009627 gardenia yellow Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000012752 quinoline yellow Nutrition 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 229940051201 quinoline yellow Drugs 0.000 description 1
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical group 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a health food prepared from vitamin E, vitamin D, folic acid and vitamin B for women in perimenopause12And auxiliary materials acceptable for health-care food. The invention accurately supplements vitamin E, vitamin D, folic acid and vitamin B12To improve estrogen disorder, prevent osteoporosis and climacteric depression, and protect cardiovascular system. The invention not only obviously improves and upgrades the prior compound vitamin product, but also is an example for implementing accurate nutrition on the physiological characteristics of perimenopausal women, and has process feasibility and good market prospect.
Description
Technical Field
The present invention relates to a vitamin nutrient composition, more precisely, it relates to a health-care food or nutrient supplement designed for perimenopausal women and having the function of preventing osteoporosis and climacteric depression.
Background
Perimenopause is the transition stage from reproductive to non-reproductive in women, also known as menopause, and usually occurs in the age of 45-55 years. In this stage, the female ovary function gradually declines, the estrogen secretion is reduced, a series of physiological and psychological changes are easily caused, and the health and the life quality of the female are influenced. Among them, osteoporosis, menopausal depression and increased risk of cardiovascular diseases are more common hidden troubles.
The incidence rate of osteoporosis of women aged over 65 in the United states is 26%, the incidence rate of osteoporosis of women aged over 50 in China is up to 30.8%, and osteoporosis of women in menopause is rapidly increasing in an exponential manner in the global range, so that the osteoporosis of the women in the menopause is a problem which cannot be ignored. The reason for this is that, in addition to fluctuation of endocrine hormone levels in menopause and influence of genetic factors, deficiency of vitamin D is also a key factor. Vitamin D deficiency is present in about 52% of middle aged and elderly women with osteoporosis in the united states, and the probability is around 68% in china.
Menopausal depression is another disease that afflicts perimenopausal women. With the advent of "estrogen withdrawal", perimenopausal women experience sustained fluctuations in steroid levels, vasomotor symptoms, and discomfort from physiological changes predispose women to anxiety, while stress and psychological shifts exacerbate mood disorders. About 35 million people worldwide are currently affected by depression, with women having about twice the incidence of men. The vitamin E can promote the secretion of sex hormone and improve female menstrual disorder and climacteric syndrome, so the supplement of the vitamin E is beneficial to perimenopausal women. In addition, serum folic acid and vitamin B in patients with depression12Levels are significantly lower than normal and need to be supplemented.
Another change brought about by menopause in women is an increased risk of cardiovascular disease and a positive correlation with increased age after menopause. The incidence of cardiovascular disease in postmenopausal women, especially women over the age of 60 years, is increasing rapidly to a level comparable to that of men. This risk-raising effect comes primarily from three areas: firstly, perimenopausal women have increased abdominal fat and myocardial fat, both risk factors for the occurrence of adverse cardiac events; secondly, the fluctuation of the female perimenopausal and female progestogen level can cause the abnormality of a renin secretion and regulation mechanism and cause the rise of blood pressure; in addition, plasma cholesterol, triglyceride, homocysteine levels may rise post-menopause, increasing the risk of atherosclerosis.
Climacteric women become an increasingly large group, and aiming at the specific physiological and nutritional requirements of the group, vitamin health care products in the market are rare at present, the problems of multiple components and low content of each component exist, and the requirements of the accurate nutritional age are not met, so that improvement is urgently needed.
Disclosure of Invention
The invention aims to provide a vitamin nutrient composition, and provides a nutritional supplement for preventing osteoporosis and climacteric depression and protecting a cardiovascular system aiming at health risks of perimenopausal women.
In order to achieve the purpose, the invention adopts the following technical scheme:
a vitamin nutritional composition containing vitamin E, vitamin D, folic acid and vitamin B for preventing osteoporosis and climacteric depression and protecting cardiovascular system12And auxiliary materials.
A compound vitamin health food comprises the following components:
(1) a vitamin E; (2) vitamin D; (3) folic acid; (4) vitamin B12(ii) a (5) Acceptable auxiliary materials for health-care food.
In the health food, the content of vitamin E is 10-500 mg, the content of vitamin D is 2-20 mug, the content of folic acid is 0.1-4.0 mg, and vitamin B12The content is 25 to 200 μ g.
Preferably, the health food has the vitamin E content of 50-400 mg, the vitamin D content of 5-20 mug, the folic acid content of 0.4-2.0 mg and the vitamin B12The content is 25-100 μ g.
The vitamin E comprises natural vitamin E (D- α -tocopherol, D- α -tocopheryl acetate, D- α -tocopheryl succinate), dl- α -tocopheryl acetate, dl- α -tocopherol, calcium succinate vitamin E and the like and any combination thereof.
The folic acid substances comprise folic acid, 5-methyltetrahydrofolic acid, leucovorin calcium, L-methylfolic acid, folate, folic acid or active metabolites of the folate, and substances capable of releasing/generating folic acid in vivo, namely various folic acid forms which comprise artificial synthesis and plant extract sources and any combination thereof.
The vitamin B of the invention12Including cobalamin, methylcobalamin, 5' -deoxyadenosylcobalamin, hydroxocobalamin, cyanocobalamin and other cobalamin derivatives and substances which can release/generate cobalamin in vivo and any combination thereof.
The vitamin D of the present invention includes vitamin D2And vitamin D3And any combination thereof.
The health food can be prepared into oral dosage forms such as common tablets, pills, granules, oral liquid, chewable tablets, soft capsules, hard capsules, powder, granules and the like.
The auxiliary materials in the invention are selected from one or a combination of a plurality of filling agents, wetting agents, bonding agents, disintegrating agents, lubricating agents, flavoring agents, stabilizing agents, embedding substances, coating premixing agents and edible pigments.
The filler comprises one or more of starch, soluble starch, dextrin, maltodextrin, potato starch, corn starch, wheat starch, D-mannitol, calcium hydrophosphate, anhydrous calcium hydrophosphate, maltose, xylitol, sorbitol, microcrystalline cellulose, isomaltulose, milk powder, low-substituted hydroxypropyl cellulose, sucrose, glucose, lactose, pregelatinized starch and the like.
The wetting agent comprises purified water and ethanol, and the adhesive comprises one or more of hydroxypropyl methyl cellulose, povidone, hydroxypropyl cellulose, sodium carboxymethyl cellulose, starch, methyl cellulose, ethyl cellulose, gelatin, polyethylene glycol, pregelatinized starch, sucrose, glucose and the like.
The disintegrating agent comprises one or more of starch, carboxymethyl starch sodium, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, sodium bicarbonate, citric acid and the like, and the lubricant comprises one or more of magnesium stearate, stearic acid, talcum powder, silicon dioxide, hydrogenated vegetable oil, polyethylene glycol, sodium dodecyl sulfate, glyceryl behenate, sodium stearyl fumarate and the like.
The flavoring agent comprises one or more of fruit powder, edible essence, high-intensity sweetener, sour agent and the like, wherein the fruit powder comprises one or more of orange powder, lemon powder, cherry powder, apple powder, strawberry powder, kiwi fruit powder, orange powder, seabuckthorn fruit powder, green plum fruit powder, mango fruit powder, mulberry fruit powder, hawthorn fruit powder, watermelon fruit powder, pineapple fruit powder, blueberry fruit powder, honey peach fruit powder, hami melon fruit powder, grape fruit powder, vanilla fruit powder, pomegranate fruit powder, rose fruit powder and the like.
The edible essence comprises one or more of vanilla essence, sweet orange essence, milk essence, apple essence, grape essence, strawberry essence, pineapple essence, honey peach essence, hami melon essence, lemon essence, cherry essence, sweet corn essence, banana essence, grape essence, rose essence, blackcurrant essence, green apple essence, mango essence, green mango essence, orange essence, fragrant orange essence, snow pear essence, green plum essence, blueberry essence, waxberry essence, grapefruit essence, pineapple essence, guava essence, passion fruit essence, kiwi fruit essence, watermelon essence, papaya essence, durian essence, litchi essence, hawthorn essence, olive essence, mulberry essence and the like.
The high-power sweetener comprises sucralose, aspartame, mogroside, neotame and stevioside, the sour agent comprises citric acid, malic acid, lactic acid, tartaric acid and fumaric acid, the edible pigment comprises caramel color, gardenia yellow, curcumin, chlorophyll, capsicum orange, capsanthin, grape skin red, carmine and aluminum lake thereof, sunset yellow and aluminum lake thereof, brilliant blue and aluminum lake thereof, indigo blue and aluminum lake thereof, beet red, natural amaranth, gardenia blue, plant carbon black, iron oxide red, black bean red, quinoline yellow, lycopene, monascus red, yellow iron oxide, cocoa shell color, safflower yellow, monascus yellow and the like.
The stabilizer comprises dibutyl hydroxy toluene (BHT), Butyl Hydroxy Anisol (BHA) and vitamin C, and the inclusion compound comprises β -cyclodextrin, α -cyclodextrin, gamma-cyclodextrin, dextrin, starch, edible modified starch, sucrose, maltodextrin, gum arabic and the like.
The invention aims at the potential health risks of perimenopausal women and accurately supplements vitamin E, vitamin D, folic acid and vitamin B12To improve estrogen disorder, prevent osteoporosis and climacteric depression, and protect cardiovascular system. The invention not only obviously improves and upgrades the prior compound vitamin product, but also is an example for implementing accurate nutrition on the physiological characteristics of perimenopausal women, and has process feasibility and good market prospect.
Detailed Description
While the following is a description of the preferred embodiments of the present invention, it should be noted that those skilled in the art can make various modifications and improvements without departing from the principle of the embodiments of the present invention, and such modifications and improvements are considered to be within the scope of the embodiments of the present invention.
Example 1: preparation of tablets of the vitamin composition according to the invention (1000 tablets)
The formula is as follows:
the preparation method comprises the following steps: preparing binder from polyvidone K30 with 50% ethanol solution, adding vitamin E and vitamin D into the binder, and stirring. Vitamin B is taken in addition12Mixing folic acid, sucralose and pregelatinized starch, sieving, adding milk essence, carboxymethyl starch sodium and dextrin, mixing, adding prepared binder containing vitamin E and vitamin D, making into soft mass, granulating with 24 mesh sieve, drying at 55 deg.C for 2 hr, grading with 24 mesh sieve, adding magnesium stearate, mixing, and tabletting. And preparing the coating premix into a solution, and coating plain tablets to obtain the tablets of the health food.
Example 2: preparation of Soft capsules (1000 capsules) of vitamin composition according to the invention
The formula is as follows:
the preparation method comprises the following steps: adding Cera flava into soybean oil, heating at 50 deg.C to dissolve Cera flava, standing to room temperature, and collecting folic acid, vitamin D, vitamin E, and vitamin B12Adding into soybean oil to obtain suspension. Preparing gelatin solution from gelatin, purified water, caramel and p-hydroxybenzoate, pelleting the obtained suspension by a pelleting machine to obtain soft capsules, and carrying out shaping, washing and drying treatment to obtain the soft capsules of the health food.
The health food prepared in this example was subjected to an animal function test and a safety toxicology evaluation test according to the evaluation method of "health food test and evaluation technical Specification" of Ministry of health.
Female castrated rats are adopted to simulate female perimenopause, and experimental verification is respectively carried out from three levels of osteoporosis improvement, climacteric depression and cardiovascular and cerebrovascular disease prevention:
1) prevention of osteoporosis and improvement of bone density and dry weight of femur
Randomly dividing SD female rats (weight 280-320 g) with 3 months of age into a pseudo-operation group, a model group, a vitamin D group and a vitamin D/E/B group12A folic acid group. Model group, vitamin D/E/B12The rats in folate group underwent ovariectomy with dorsal double incision approach, and the sham group underwent the same approach to excise a small amount of fat near the ovaries. After 4 weeks of postoperative conventional feeding, rats were subjected to intragastric administration: the sham operation group and the model group are both given 0.9% sodium chloride injection 10ml/kg, and the vitamin D group is given vitamin D120 ug/kg, vitamin D/E/B12Administering vitamin D + vitamin E + vitamin B to folic acid group12+ Folic acid (0.12+1.2+1.0+2.0) mg/kg, drench stomach continuously for 12 weeks.
At the end of week 12, rats were sacrificed, free both hind leg femurs, removed surrounding tissue, the femurs were placed on a small animal platform, placed along the long axis of the platform, and femoral bone density (BMD) was measured using a dual energy X-ray bone densitometer. The right femur was then removed of muscle and connective tissue, dried in an oven at 120 ℃ for 1h, cooled and weighed on a ten-thousandth scale as the dry weight of the right femur. The statistical test method adopts t test.
The experimental results are as follows:
table 1 the results of the experiments show that BMD (P) of femurs of all rats in the model group is significantly reduced compared with that in the sham operation group<0.05), which shows that the castration of a female rat can cause the reduction of bone density, and is similar to the osteoporosis of a human female in perimenopause, and is an ideal model of the experiment; compared with the bone density of the thighbone of rats in the model group and the vitamin D group, the vitamin D/E/B12The femoral bone density of rats in the folic acid group is obviously increased, which shows that the compound composition can resist the reduction of BMD caused by the reduction of estrogen secretion, and the effect is obviously stronger than that of the vitamin D which is used alone. The bone strength is mainly determined by the bone mass, and BMD (bone Mass Detector), namely the amount of bone mineral contained in unit bone area, is a main index reflecting the bone strength and the bone mass and is an important index currently used for osteoporosis diagnosis and fracture risk evaluation.
TABLE 1 vitamin D/E/B12Effect of Folic acid on bone density of femurs of castrated female rats: (
n＝12)
Note: in comparison with the set of models,aP<0.05; compared with the vitamin D group,bP<0.05; compared with the group of the pseudo-operation,cP<0.05。
table 2 shows the dry weight data of the right femur for each group, which shows that the dry weight of the right femur is reduced in other groups of rats compared with the sham operation group; the dry weight of the right femur was increased in the vitamin D group and the vitamin D/E/B12/folate group as compared to the model group, and the vitamin D/E/B12The increase in the folate group is statistically significant (P)<0.05); vitamin D/E/B12The dry weight increase of right femur of folic acid group is higher than that of vitamin D group by simple gavageTrend, suggesting vitamin D/E/B12The folic acid compound combination has more obvious effect on increasing the dry weight of the right femur and improving the bone density of castrated female rats compared with the vitamin D which is only orally taken.
TABLE 2 vitamin D/E/B12Effect of Folic acid on the Dry weight of the Right femur of castrated female rats: (
n＝12)
Note: compared with the group of the pseudo-operation,aP<0.05; in comparison with the set of models,bP<0.05。
2) improving depression and improving rat behavioral score and serum 5-hydroxytryptamine level
SD female rats (weight 280-320 g) with 3 months of age are randomly divided into a normal group, a model group and vitamin B12Group, vitamin D/E/B12A folic acid group. Model group, vitamin B12Group, vitamin D/E/B12The rats in folate group underwent ovariectomy with dorsal double incision approach, and the sham group underwent the same approach to excise a small amount of fat near the ovaries. After the operation, the animals are fed for 4 weeks, and then 1 animal is fed in each cage, and the animals receive various stresses for 42d, including electric foot sole shock (36V alternating current, 1 stimulation for 1 time every 1min, 10s continuously, and 30 times totally), ice water swimming (4 ℃, 5min), heat stress (45 ℃, 5min), shaking (1 time/s, 15min), tail clamping (1min), water deprivation (24h), fasting (48h), stimulation of day and night, and the like, wherein each stimulation is carried out for 2 times on average, and 4 rounds of stimulation are stimulated according to the stimulation sequence. During the stress period, rats were also subjected to the following intragastric administration: the normal group and the model group are both administered with 10ml/kg of 0.9% sodium chloride injection and vitamin B12Group administration of vitamin B121.2mg/kg, vitamin D/E/B12Administering vitamin D + vitamin E + vitamin B to folic acid group12+ Folic acid (0.09+1.2+1.2+2.0) mg/kg.
Behavioral assay (Open-Field method): the utility model adopts an open box without a solid column, the height is 40cm, the length and the width are respectively 80cm, the peripheral wall is black, and the ground is composed of 25 blocks with equal area. The number of the ground blocks crossed by the animals is taken as horizontal movement score (crossing), the animals pass through 1 grid for 1 time, and if the animals walk in a straight line, the animals walk 1 time per 10 cm. The measurement was carried out on days 21, 28, 35 and 42 of the experiment. Each rat was treated 1 time, 3 min/time.
Sugar water consumption experiment: rats were housed in a single cage, and 120ml of 10g/L sucrose solution was administered to each animal while fasting for 24 hours, and the amount of 10g/L sucrose solution consumed by the animals was calculated.
Serum 5-hydroxytryptamine assay: detection by an HPLC method: 1) mobile phase: 0.1mol/L sodium acetate (PH 5.09), with methanol at 9: 1 and mixing. 2) Sample pretreatment: collecting blood 2ml from femoral artery of each rat, separating out 200ul serum, mixing with 1.2ml ethyl acetate, centrifuging at 4 deg.C for 15min at 15000r/min, collecting supernatant, drying under reduced pressure, adding 100ul mobile phase, and sampling 20ul for detection. 3) Chromatographic conditions are as follows: the chromatographic column Synergi 4u Fusion-RP 80A, 250 multiplied by 4.60mm, the column temperature of 25 ℃, the flow rate of 1.0Ml/min, the emission wavelength of 330nm and the excitation wavelength of 290 nm.
The number of times of standing is taken as the vertical activity score (earing), and the animal's feet leave the ground as a sign, and 1 activity is taken no matter how long the animal stands until the feet are put down. The horizontal activity reflects the activity of the animal, the vertical activity reflects the curiosity of the animal in the fresh environment, and the sugar water consumption reflects the reward reaction degree of the animal. 5-hydroxytryptamine (5-HT) is a neurotransmitter closely associated with the onset of depression, and is involved in the regulation of emotion, memory, appetite and sexual function, and when its content is reduced, it can cause depression.
The experimental results are as follows:
as shown in tables 3 and 4, vitamin B was compared with the model group12Group and vitamin D/E/B12Trend of improving folic acid group behavior score, sugar water consumption and serum 5-hydroxytryptamine content, wherein vitamin D/E/B12The horizontal integral and sugar water consumption of the folate group increased significantly (P)<0.05), and vitamin D/E/B12Vitamin B alone in folic acid composition ratio12The group improved more effectively (P)<0.05)。
TABLE 3 Open-Field score and sugar water consumption of rats in each group: (n＝10)
Note: in comparison with the normal group,aP<0.05; in comparison with the set of models,bP<0.05, with vitamin B12The comparison of the groups is carried out,cP<0.05。
TABLE 4 serum 5-hydroxytryptamine content in groups of rats: (
n＝10)
Note: in comparison with the normal group,aP<0.05; in comparison with the set of models,bP<0.05。
3) preventing cardiovascular diseases and reducing plasma low density lipoprotein, Hcy and malondialdehyde
Randomly dividing SD female rats (weight 280-320 g) with 3 months of age into a pseudo-operation group, a model group, a folic acid group and vitamin D/E/B12A folic acid group. Model group, folic acid group, vitamin D/E/B12The rats in folate group underwent ovariectomy with dorsal double incision approach, and the sham group underwent the same approach to excise a small amount of fat near the ovaries. After the postoperative conventional rearing for 4 weeks, the following intragastric administration treatments are respectively carried out: the sham operation group and the model group were administered with 10ml/kg of 0.9% sodium chloride injection, and the folic acid group was administered with 2.4mg/kg of folic acid and vitamin D/E/B12Administering vitamin D + vitamin E + vitamin B to folic acid group12+ Folic acid (0.09+1.2+1.2+2.4) mg/kg, and the contents of Total Cholesterol (TC), low-density lipoprotein (LDL) and homocysteine (Hcy) in serum were measured after 8 weeks.
The experimental results are as follows:
as shown in tables 5 and 6, vitamin D/E/B was compared with the model group12Both folic acid and folic acid significantly reduced Hcy levels (P) when used alone<0.05), and vitamin D/E/B12The reducing effect of the folic acid compound is obviously better than that of folic acid which is used alone. Vitamin D/E/B12Folic acid and folic acid both have a tendency to reduce plasma oxidized low density lipoprotein, and vitamin D/E/B12The effect of the folic acid combination on the reduction is statistically significant (P)<0.05). Lipid Peroxides (LPO) on serum and artery walls are parallel to atherosclerosis, lipid peroxide metabolite is Malondialdehyde (MDA), and the detection of MDA content can reflect the degree of lipid peroxidation of blood vessels, namely the degree of atherosclerosis. As shown in Table 7, after 8 weeks of gastric lavage, the folic acid group and vitamin D/E/B were compared with the model group12Folate serum and arterial wall malondialdehyde were significantly reduced (P)<0.05), and vitamin D/E/B12The folate group had a tendency to decrease the effect better than the folate group, indicating vitamin D/E/B12Folic acid has stronger effects of preventing arteriosclerosis and protecting cardiovascular function than folic acid used alone.
TABLE 5 vitamin D/E/B12Effect of Folic acid on oxidized Low Density lipoprotein (oxLDL) in castrated female rats
Note: compared with the group of the pseudo-operation,aP<0.05; in comparison with the set of models,bP<0.05。
TABLE 6 vitamin D/E/B12Effect of Folic acid on homocysteine (Hcy) in castrated female rats
Note: compared with the group of the pseudo-operation,aP<0.05; in comparison with the set of models,bP<0.05; in comparison with the folic acid group,cP<0.05。
TABLE 7 vitamin D/E/B12Effect of Folic acid on Malondialdehyde (MDA) levels in castrated female rats
Note: compared with the group of the pseudo-operation,aP<0.05; in comparison with the set of models,bP<0.05; in comparison with the folic acid group,cP<0.05。
example 3: preparation of vitamin composition hard capsules (1000 capsules)
The formula is as follows:
the preparation method comprises the following steps: mixing folic acid with 20% microcrystalline cellulose, sieving, and adding vitamin E, vitamin D, and vitamin B12Mixing, gradually mixing the obtained raw material mixture with the rest microcrystalline cellulose in equal amount, adding lactose and magnesium stearate, mixing, filling by using a full-automatic capsule filling machine, and polishing to obtain the hard capsule of the health food.
Example 4: preparation of granules of the vitamin composition of the invention (1000 parts by weight)
The formula is as follows:
the preparation method comprises the following steps: pulverizing sucrose, and sieving with 100 mesh sieve; preparing binder from polyvidone K30 with 50% ethanol solution, adding vitamin E and vitamin D into the binder, and stirring. Another folic acid and vitamin B12Mixing with cane sugar, sieving, adding apple powder, apple essence, carboxymethyl starch sodium and maltodextrin, mixing, adding prepared binder containing vitamin E and vitamin D to prepare soft material, granulating with 24-mesh sieve, drying at 55 deg.C for 2 hr, and grading with 24-mesh sieve to obtain the invented health-care food granules.
Example 5: preparation of chewable tablets (1000 tablets) of the vitamin composition according to the invention
The formula is as follows:
the preparation method comprises the following steps: preparing hydroxypropyl methylcellulose E5 into adhesive with 60% ethanol solution, adding vitamin E and vitamin D into the adhesive, and stirring. Another folic acid and vitamin B12Mixing with microcrystalline cellulose, sieving, adding stevioside, lemon essence, milk powder and xylitol, mixing, adding prepared binding agent containing vitamin E and vitamin D to prepare soft material, granulating by using a 24-mesh sieve, drying for 2 hours at 55 ℃, granulating by using the 24-mesh sieve, adding magnesium stearate, mixing, and tabletting to obtain the chewable tablet of the health food.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.
Claims (7)
1. A vitamin composition comprises the following components:
1) 10-500 mg vitamin E;
2) 2-20 μ g vitamin D;
3) 25-200 mug vitamin B12；
4) 0.1-4.0 mg folic acid;
5) acceptable auxiliary materials for health-care food.
2. The vitamin composition according to claim 1, wherein the vitamin E content is 50 to 400mg, the vitamin D content is 5 to 20 μ g, and the vitamin B12The content is 25-100 μ g, and the folic acid content is 0.4-2.0 mg.
3. The vitamin composition of claim 1, wherein the vitamin E comprises natural vitamin E (D- α -tocopherol, D- α -tocopheryl acetate, D- α -tocopheryl succinate), dl- α -tocopheryl acetate, dl- α -tocopherol, calcium vitamin E succinate, and any combination thereof.
4. The vitamin composition of claim 1, wherein the vitamin D comprises vitamin D2And vitamin D3And any combination thereof.
5. The vitamin composition according to claim 1, wherein the folic acid compounds comprise folic acid, 5-methyltetrahydrofolic acid, leucovorin calcium, L-methylfolic acid, folic acid salts, folic acid or active metabolites of folic acid salts and substances that release/generate folic acid in vivo.
6. The vitamin composition according to claims 1 to 5 can be prepared into common tablets, chewable tablets, soft capsules, hard capsules and granules or can be combined with common food for nutrition reinforcement to form health food.
7. Use of the vitamin composition according to claims 1 to 6 for the preparation of a health food for the prevention of osteoporosis, menopausal depression and reduction of the risk of cardiovascular diseases in perimenopausal women.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810867012.2A CN110786516A (en) | 2018-08-01 | 2018-08-01 | Nutritional supplement suitable for perimenopausal women |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810867012.2A CN110786516A (en) | 2018-08-01 | 2018-08-01 | Nutritional supplement suitable for perimenopausal women |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110786516A true CN110786516A (en) | 2020-02-14 |
Family
ID=69425499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810867012.2A Pending CN110786516A (en) | 2018-08-01 | 2018-08-01 | Nutritional supplement suitable for perimenopausal women |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110786516A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807586A (en) * | 1996-07-30 | 1998-09-15 | Energetics, Inc. | Method of dietary supplementation |
| CN106798337A (en) * | 2017-01-18 | 2017-06-06 | 深圳泰乐德营养与健康有限公司 | A kind of nutritious supplementary pharmaceutical suitable for the elderly |
| CN106858608A (en) * | 2017-02-14 | 2017-06-20 | 深圳泰乐德营养与健康有限公司 | A kind of alimentation composition for being beneficial to patients with depression health |
| CN106901378A (en) * | 2017-03-10 | 2017-06-30 | 深圳奥萨医疗有限公司 | A kind of health food suitable for women |
| CN106942747A (en) * | 2017-03-22 | 2017-07-14 | 深圳奥萨制药有限公司 | A kind of health food for being applied to the elderly |
| CN106974292A (en) * | 2017-03-22 | 2017-07-25 | 深圳泰乐德营养与健康有限公司 | A kind of vitamin combination health food being made up of vitamin D, E and folic acid |
-
2018
- 2018-08-01 CN CN201810867012.2A patent/CN110786516A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807586A (en) * | 1996-07-30 | 1998-09-15 | Energetics, Inc. | Method of dietary supplementation |
| CN106798337A (en) * | 2017-01-18 | 2017-06-06 | 深圳泰乐德营养与健康有限公司 | A kind of nutritious supplementary pharmaceutical suitable for the elderly |
| CN106858608A (en) * | 2017-02-14 | 2017-06-20 | 深圳泰乐德营养与健康有限公司 | A kind of alimentation composition for being beneficial to patients with depression health |
| CN106901378A (en) * | 2017-03-10 | 2017-06-30 | 深圳奥萨医疗有限公司 | A kind of health food suitable for women |
| CN106942747A (en) * | 2017-03-22 | 2017-07-14 | 深圳奥萨制药有限公司 | A kind of health food for being applied to the elderly |
| CN106974292A (en) * | 2017-03-22 | 2017-07-25 | 深圳泰乐德营养与健康有限公司 | A kind of vitamin combination health food being made up of vitamin D, E and folic acid |
Non-Patent Citations (4)
| Title |
|---|
| 李鸿霞等: "不同剂量维生素D加钙防治围绝经期妇女骨质疏松症的安全性研究", 《中国医学创新》 * |
| 闫华等: "口服叶酸及维生素B_(12)对围绝经期妇女同型半胱氨酸的影响", 《生殖医学杂志》 * |
| 陶静 等: "戊酸雌二醇单药或联合叶酸、维生素B12治疗围绝经期抑郁症的疗效比较", 《南昌大学学报(医学版)》 * |
| 马惠君 等: "维生素D与抑郁症关系的研究进展", 《中西医结合心脑血管病杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11219590B2 (en) | Anti-aging agent and anti-aging method | |
| CN107232611B (en) | A nutritional composition comprising vitamin D, K and folic acid | |
| ES2380060T3 (en) | Pharmaceutical compositions of a neuroactive steroid and uses thereof | |
| JP2009511522A (en) | New use of nutraceutical composition | |
| US20220031596A1 (en) | Anti-aging agent and anti-aging method | |
| CN106858608B (en) | Nutritional composition beneficial to health of depression patients | |
| US20220023266A1 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| CN106798337B (en) | Nutritional supplement suitable for middle-aged and elderly people | |
| JP2020533012A (en) | Composition for prevention, improvement or treatment of osteoarthritis containing Masuchi extract as an active ingredient | |
| WO2004089359A1 (en) | Composition for inhibition or prevention of bone density lowering and refreshment therefor | |
| CN106942747A (en) | A kind of health food for being applied to the elderly | |
| CN106974292B (en) | A vitamin composition health food comprising vitamin D, E and folic acid | |
| CN107136514B (en) | A health food containing vitamin D, K and vitamin B12Composed nutrient composition | |
| CN110786516A (en) | Nutritional supplement suitable for perimenopausal women | |
| US20130164342A1 (en) | Formulations for osteoporosis | |
| JP2009184940A (en) | Therapeutic agent | |
| WO2020077915A1 (en) | Novel use of hydroxytyrosol and derivative thereof in preparing anti-depressant product | |
| US20230255942A1 (en) | Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia | |
| CN106923346B (en) | Selected composite vitamin health product and application thereof | |
| CN106901379A (en) | A kind of vitamin health food of auxiliary prevention of cardiovascular disease | |
| CN107125768B (en) | A health food containing vitamins D, E and B12Composed nutrient composition | |
| CN109588727B (en) | Health food for auxiliary prevention of cardiovascular diseases | |
| CN112957334A (en) | Pharmaceutical composition containing ALPELISI | |
| CN107156816B (en) | Health food suitable for people with early diabetes and metabolic syndrome | |
| WO2019004984A2 (en) | A pharmaceutical formulation comprising cholecalciferol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200214 |